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Summary
Clinical peptidomics and metabolomics are two emerging
“-omics” technologies with the potential not only to detect
disease-specific markers, but also to give insight into the
disease dependency of degradation processes and metabol-
ic pathway alterations. However, despite their rapid evol-
ution and major investments, a clinical breakthrough, such
as the approval of a major cancer biomarker, is still out of
sight. What are the reasons for this failure? In this review
we focus on three important factors: sensitivity, specificity
and the avoidance of bias.
The way to clinical implementation of peptidomics and
metabolomics is still hampered by many of the problems
that had to be solved for genomics and proteomics in the
past, as well as new ones that require the creation of new
analytic, computational and interpretative techniques. The
greatest challenge, however, will be the integration of in-
formation from different “-omics” subdisciplines into
straightforward answers to clinical questions, for example,
in the form of new, superior “meta-markers”.
Key words: peptidomics; metabolomics; sensitivity;
specificity; bias; preanalytics; bioinformatics; data
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Introduction
In the past decade, the emerging “-omics” technologies
for the rapid profiling of large numbers of peptide and
metabolite markers with mass spectrometry evoked great
hopes of detecting new disease biomarkers [1]. High-im-
pact publications in the fields of proteomics [2], peptidom-
ics [3] and metabolomics [4] laid the ground for the ex-
pectation that it would be possible to broaden the, as yet,
very small spectrum of markers available today, especially
for the early detection of malignancy, through the use of
easy-to-use high-throughput technologies. However, des-
pite major investments in these fields, despite the ever-ad-
vancing refinement of the analytical techniques, and des-
pite the broadening and deepening of our pathophysiolo-
gical knowledge, no new major cancer biomarker has been
approved for clinical use in the past 25 years [5, 6]. On
the contrary, the above-mentioned ground-breaking public-
ations in particular have been disproved [7–9], after a first
closer look at preanalytics, study design and data evalu-
ation. But why did they fail?
To answer this intriguing question, it may be necessary
first to illustrate the biomarker concept. The idea behind
a diagnostic “biomarker” (amongst other definitions) is to
find a measurable entity that sensitively, specifically and
without any bias indicates the presence, progression or ab-
sence of a disease state or its surrogate [5]. Such entities
can be the presence of proteins, peptides or metabolites,
as well as changes in their concentrations or ratios thereof,
or even complex interactions depicted in similarly complex
algorithms. An extensive overview of the different types
of biomarkers and the stages of their development was re-
cently published by Ziegler et al. [10]. In proteomics re-
search, markers are usually considered to be proteins pro-
duced or shed in lesser or greater amounts by tumour cells
than by healthy tissue. In peptidomics, the altered peptides
are assumed not only to arise from tumour tissue, but also
to be altered in vivo or ex vivo by tumour-specific pro-
cesses and enzymes such as proteases [11]. In metabolom-
ics, finally, the metabolite markers themselves are not con-
sidered as tumour-specific products, but rather their altered
correlations and metabolic pathways (e.g. in the context
of the well-known Warburg effect [12, 13]) lead to con-
centrations and patterns of metabolic intermediates or end-
products that are different in health and disease [14]. These
alterations can be seen as surrogate markers – associated
with, but frequently not causally connected to, the underly-
ing disease. In a wider approach, different “-omics” tech-
niques, and even clinical data, can be assembled to create
new “meta-markers” from panels of different analytes in
order to add predictive value [15, 16], and their complex
interactions can be computationally elucidated [17]. The
major challenges, however, in the search for such markers,
panels, or models thereof, are sensitivity, specificity and
the avoidance of bias [18].
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Sensitivity
Sensitivity still is a demanding task in proteomics/pep-
tidomics, as well as in metabolomics. In this context, it is
the ability of an analytical method to generate “positive”
results for a group of individuals defined as “affected”.
This can be achieved either when marker concentrations
are high enough to be easily detected, or by use of soph-
isticated technologies capable of tracing even the smallest
amount of putative marker analytes slightly above or, in
extreme cases, within the noise level [19]. Thus, the two
major fields of potential improvement are analytics and
evaluation. When the SELDI-TOF methodology (surface-
enhanced laser desorption/ionisation mass spectrometry)
was clinically introduced 10 years ago, it was – without
any doubt – an analytical revolution, but not in terms of
sensitivity. Therefore, it was no surprise that the first mark-
ers identified from SELDI profiles were highly abundant
and very well-known serum proteins or fragments [20].
Regarding the concentration ranges of the conventional tu-
mour markers used hitherto, there might be a factor of
104 gap unbridgeable with contemporary mass spectromet-
ric screening equipment [21]. And even with, for example,
conventionally assayed cancer antigen-125 (CA-125),
which has a detection limit as low as 1.5 kU/l, for the early
detection of ovarian cancer, the “biomarker lead time”
might last more than 10 years, as Hori and Gambhir re-
vealed by mathematical modelling of tumour growth, shed-
ding and marker elimination [6, 22].
Although the analytical sensitivity is increased many-fold
with any new generation of mass spectrometry instruments,
detection limits still remain the major technical challenge
in clinical peptidomics and metabolomics [23]. Also, when
we started our clinical studies using MALDI-TOF MS
(matrix-assisted laser desorption/ionisation mass spectro-
metry) with pancreatic cancer as a model disease, the only
marker we could detect and identify was platelet factor
4 (PF4) [24]. Since PF4 is an analyte clinical chemistry
has been acquainted with for many years, we could readily
verify our results with a commercially available enzyme-
linked immunosorbance assay (ELISA). To enhance se-
lectivity we used in our study one further technique, which
has been proposed as a possible way out of the sensitivity
dilemma by Hori and Gambhir as well as many others: the
generation of compound marker models or “meta-markers”
[15, 22, 25, 26]. The idea behind this concept is that dif-
ferent markers can explain different aspects of the over-
all variance in a dataset by providing different perspectives
on a certain disease and, therefore, may exert additive ef-
fects when optimally combined together. Besides several
limitations recently outlined by Pepe et al. and Pencina [25,
27], and the certain need to keep in mind Occam’s law of
parsimony (which states that the exclusion of unnecessary
variables probably leads to better models) to avoid data
overfitting [28], this definitely is a promising approach to
explaining multifactorial phenotypes with multivariate pre-
dictors. The measurement of single peptidomic or meta-
bolomic markers may not exceed the selectivity of con-
ventional tumour markers [28]. However, combinations of
expression profiling, imaging technologies such as com-
puter tomography, magnetic resonance imaging or positron
emission tomography, and even other sources of inform-
ation about the patient (e.g. epidemiological data), might
lead to a substantial increase in sensitivity. In this context,
“-omics” technologies, conventional laboratory medicine
and imaging should not be seen as separate disciplines, but
as complementary approaches to the same diagnostic ques-
tion. For the merging and modelling of compound “meta-
markers”, however, a further abstraction step in medical
imaging that resolves image data to qualitative or quantit-
ative features is necessary.
Another approach to increase sensitivity is the use of en-
richment techniques in the sampling and sample prepara-
tion phase, including in-vivo sampling, optimised extrac-
tion methodology and preconcentration steps [29], as well
as the application of mass spectrometric ion collection
methods such as ion traps [23]. The third way to increase
sensitivity might be a radical shift of the researchers’ per-
spective from molecules shed or modified directly by a tu-
mour or a certain disease towards large-scale meta-effects,
which are well known in, for example, malignant disease
(sweating, weight loss, etc.), and are mainly metabolism
based and, therefore, an optimal target for metabolite pro-
filing and metabolomics [3]. Of course, such metabolic al-
terations themselves might not be very specific, but there is
hope of finding specific patterns based on multiple interac-
tions of diseases with key enzymes of metabolic pathways
[30], leading to a set of a few, easy-to-quantitate metabolic
markers. Since these metabolic effects are so pronounced
that they frequently generate a prima vista phenotype, like
malignant cachexia [31], they should be large enough to
be detectable with today’s imperfect profiling technology
[32].
Specificity
Specificity is the second challenge on the way to the suc-
cessful implementation of proteomics/peptidomics and
metabolomics in clinical diagnostics and practice. Speci-
ficity is herein defined as the capability of a marker to as-
sign “negative” values to subjects defined as “nonaffec-
ted”. The problem with this definition is that, especially in
matched control studies, the “nonaffected” are a highly se-
lected subgroup, of the general population in the case of
screening markers and of the patient group in the case of a
discriminative disease marker. This may lead to a situation
in which a suggested “new” biomarker performs extremely
well in a matched-control study environment, but loses all
selectivity when used in, for example, a clinical setting
with many potential differential diagnoses [27], where the
principal differentiation between “healthy” and diseased is
trivial. Therefore, when the discriminative power of a pro-
posed biomarker is reported, it is essential to take the com-
position of the disease and control groups into considera-
tion.
Another problem also depends on the size and composition
of the study groups, so-called “overfitting”, which denotes
the “overspecification” of a model on the basis of irrelevant
variables. If we search, for example, for differences
between two groups, we might find “markers” that separate
the groups stunningly well, but are not related to the clas-
sification criterion itself. Especially when the study groups
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are small and large numbers of potential “markers” are in-
vestigated, the usual 5% error level leads to one statistic-
ally “significant” but random marker out of 20, especially
when heuristic approaches are applied. For this pitfall, sev-
eral solution strategies are available. The first is to increase
the number of subjects compared: if the number of ob-
served variables is the same, the probability that the dif-
ferences therein are random decreases. That might sound
simple, but to obtain high-quality samples from well-doc-
umented patients in a reasonable timeframe can be a real
challenge, especially for smaller diagnostic centres. If sev-
eral variables are under investigation, the corresponding
p-values should be adjusted accordingly. Additionally, the
study groups should resemble the heterogeneity of the pop-
ulations for which a “marker” is designed in an optimal
way, in order to avoid findings that are selective only for
a small subpopulation. The next possibility is the applic-
ation of split-half [18] or crossover study designs [24],
internal cross-validation, or bootstrapping [33]. Although
these methods are generally recommended, they neverthe-
less may be prone to bias [34]. The third and probably best
way to avoid overfitting remains totally independent, ex-
ternal validation of the results. That means that the valid-
ating group investigates a previously published “marker”
with an independent team, independent patients and an in-
dependent analytical platform [5, 18]. However, not even
this “gold standard” of validation is free of bias, when, for
example, the independence is compromised, or only the
best datasets or models are reported [34]. In an optimal
case, all three solutions should be applied complementarily.
A further, frequently neglected point is that the specificity
of a predictive model strongly depends on the selected
cut-off, and that even predictive models that perform well
lead to wrong decisions if the cut-off level is not set ad-
equately [35]. In a recent publication, Pepe et al. [27] out-
line another threat to specificity: the distortion of the distri-
bution of relevant risk factors by matching, which can lead
to false estimation of the predictive performance of a bio-
marker when it is correlated to a matched risk factor. Also,
the computation of the gain in specificity achieved by in-
corporating a new marker into an existing model (“added
value”) is a nontrivial task far beyond simply detecting a
significant difference between receiver operator character-
istic (ROC) curves [15, 35, 36].
Avoidance of bias
The third, and probably greatest, challenge in biomarker re-
search is the avoidance of bias. Bias is defined as an un-
intentional, unconscious, systematic, erroneous association
of some characteristic(s) within a group, in a way that dis-
torts comparison with another group [18]. In other words,
a covariate we are not aware of. This unawareness is the
principal problem of any kind of bias – if we a priori knew
(and appropriately remembered) the potential sources of bi-
as, we could address them in the design of our studies. And
they are legion! Some of them were already mentioned in
the preceding paragraphs, but their range covers the com-
plete process from study concept, subject selection, the
preanalytical phase, measurement, postprocessing and in-
terpretation. Especially in metabolomics, which is defined
as the unbiased analysis of all metabolites in a defined sys-
tem [23, 37] and usually performed within observational
study designs, the avoidance of bias is critical [38].
Study concept
The fundamental problem in observational studies is
“equality at baseline”: the claim that controls and patients
in, for example, a metabolomics study are equal in all
measurable variables except for disease [18, 38], thus ren-
dering the disease-specific differences obvious. Whereas
such equality can be guaranteed by the law of large num-
bers in an experimental study design when, for example,
diseased patients are randomly assigned to one of several
treatment strategies, it is nearly impossible to select pa-
tients and controls who are perfectly matched in all vari-
ables of relevance, especially when the relevance first be-
comes apparent during the study course. Indeed, by op-
timally matching patients and controls, researchers create a
synthetic “nonclinical” or “nonepidemiological” situation,
Figure 1
The biomarker bottleneck. During the successive phases of the
transition of a biomarker from bench to bedside (roughly
segmented into exploratory “discovery”, multicentred “validation”,
clinical assay “development”, and large-scale “deployment”
phases), the hurdles for successful evolution are steeply
increasing. Researchers face exploding costs and complex
regulatory requirements, and they have to cooperate with
competing groups to gain large and independent validation cohorts.
Finally, few – if any – markers can be clinically established.
Figure 2
Potential sources of preanalytical bias.
RT = room temperature.
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which impedes evaluation of marker performance by dis-
torting true prevalences and thereby a priori probabilities
[27].
Another key question for study design is: to split or not
to split? Today, splitting the study cohort into a “training”
group in which, for example, discriminatory models are
generated, and a “validation cohort”, which is used to veri-
fy the diagnostic performance of the marker models, is gen-
erally accepted. In principle, there are three ways to per-
form splitting. First, so-called internal cross-validation, in
which a part of the cohort (e.g. 20%) is left out, and the
other part (80%) is analysed. The analysis procedure is
then repeated four times, each with another 20% left out.
The most extreme case of this k-fold cross-validation ex-
cludes just one subject at a time and is called the “jack-
knife” method. These methods are, however, prone to bias
and their inappropriate application might lead to inflated
estimates of classification accuracy [34]. The aforemen-
tioned split-half approach omits the k-fold resampling and
simply uses one part (usually 50%) of the cohort as a
training set and the other part as a validation set. But this
method also has a severe drawback. Knottnerus and Muris
stated that “it only evaluates the degree of random error
at the cost of even increasing such error by reducing the
available sample size by 50%” [39]. They propose a third
way to split cohorts: the “totally independent” and truly
external evaluation. In this, the metastudy cohorts consist
of independently collected and analysed subcohorts from
different centres and investigators. This third way is prob-
ably the optimal procedure to detect (and thereafter avoid)
sources of bias related to centre-specific features such as
different patient preparation, different preanalytical pro-
Figure 3
Complexity of the conventional “hypothesis-driven” approach (A)
compared with “hypothesis-free” study approaches (B & C). Most of
the published metabolomics studies resemble study type C:
differences are determined and principal component analysis (PCA)
score plots are frequently drawn. But since complexity is not really
reduced, interpreting the data and answering the study questions is
difficult and sometimes impossible. Study type B includes a
complexity reduction step (e.g. variable/model selection, see
orange circle) and thereby facilitates interpretation. Elaborate
statistics are necessary to perform this reduction, but they are
unavoidable since the complexity of the information contained in
the “-omics” data usually exceeds human comprehension (the
“comprehensibleness threshold” signifies this limit).
tocols (or their different observance), different analytical
methods and different interpretation of the measurement
results in the various study centres when they depend on
individual ratings. On the other hand, “externality” might
be the most difficult task, because many variables have to
be fitted across different centres, and researchers have to
collaborate with potentially competing groups and rely on
the protocol adherence of their colleagues to get the results
validated. Another problem might be the opinion of many
expert reviewers that it would be necessary to demand “ex-
ternal” validation for any kind of biomarker study, while
being unaware that truly “external” means that their claims
should be addressed to other, “external” groups.
Another important aspect that Rifai et al. [40] and Ziegler
et al. [10] mention is the “staging” of biomarker studies.
As in tumour development, the “early stage” studies are
small and single-centre, whereas the “late stage” studies
include multiple centres and grow to population scale. In
the “discovery phase” a first pilot investigation of several
tens to a hundred samples are analysed and, usually by
means of differential analysis, potential “biomarkers” are
identified. Such studies are easy to perform, are (so far)
published fast and, once the analytical equipment is avail-
able, also not very expensive. The vast majority of pub-
lished “-omics” biomarker studies can be assigned to this
category, although they frequently are not appropriately la-
belled as “pilot” or “preliminary” investigations. Hence,
a huge number of “potential” biomarkers could be avail-
able for further validation – which is never done, because
the subsequent validation phases are expensive, need larger
sample collections (which are frequently not available)
and, in the case of multicentre studies, require cooperation
with possibly competing researchers. These phases com-
prise, for example, external validation, assay refinement,
prospective evaluation and, finally, the development, ap-
proval and deployment of a (commercial) clinical assay
(fig. 1). Unfortunately, the financial and regulatory require-
ments, as well as the risks of failure, of these later stages
exceed the capabilities of most research groups, and as long
as funding is granted because there is “a lack of biomark-
ers” (which is essentially wrong, because there is primarily
a lack of validated biomarkers), researchers will continue
to flood scientific literature with preliminary, nonreplicable
and biased “markers”.
A frequently overlooked pitfall is the loss of generalis-
ability. If the cohorts of healthy controls and patients are
selected in accordance with very strict selection criteria,
they only represent “special cases”. If a model is built
thereon, it might perfectly discriminate these cohorts, but
after translation into clinical practice, the usual compos-
ition of affected and nonaffected cohorts will vary con-
siderably, and the results will not be replicable. The diffi-
culty with this situation is that it cannot be resolved, even
with external validation, when the same eligibility criter-
ia are applied in training and validation studies. Therefore,
an extensive display of the “descriptives” is mandatory in
publications of biomarker studies to enable physicians to
evaluate subsequently whether their patients fit into the re-
spective target cohort and are suitable for the diagnostic
procedure. In this context, at least three points are import-
ant. Firstly, the standardisation, which is necessary without
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any doubt, should not narrow the patient spectrum down
to a collection of “special cases” when a diagnostic meth-
od is proposed for general application. In contrast, although
the preanalytical influences should be as controlled as pos-
sible, the biological variability in the samples should re-
semble the future target population and therefore include,
for example, typical comorbidities in the patient as well as
in the control group. Secondly, an evaluation plan should
be set up before the sample collection starts. At the mo-
ment, many biomarker studies are “passively” designed,
based on pre-existing sample collections, which are com-
pared simply because they are available. Samples should be
collected prospectively and focused on a specific target, be-
cause only under these conditions can they be collected in
a way that takes into account all the aforementioned points
[41]. Thirdly, biomarker studies should be recorded in a
uniform register providing all the information necessary for
external scientists to perform validation studies [42, 43].
Preanalytical phase
The first disappointment after the “proteomics hype” arose
mainly from preanalytical issues [1]. Basic principles well
known in laboratory medicine had to be reinvented when
the quest for new disease biomarkers began in the emerging
“-omics” technologies. Probably the most famous arche-
type of a nonreproducible biomarker study was reported
in the ground-breaking publication of Petricoin et al. [2],
which proposed “an iterative searching algorithm that iden-
tified a proteomic pattern that completely discriminated
cancer from noncancer”. Two years later, Baggerly et al.
[44] reanalysed the datasets, identified many analytical and
bioinformatic shortcomings, and finally could not repro-
duce the results. Another notable example was the sug-
gestion by Xu et al. that lysophosphatidic acid was a bio-
marker for ovarian cancer [45]; this even led to a failed
commercial validation attempt. A few years later, the se-
lectivity of this biomarker was disproved in a subsequent
study [46]; as Eleftherios Diamandis states, the uncon-
trolled leakage of lysophosphatidic acid from blood cells
introduced preanalytical biases in the results [5]. In the
field of metabolomics, Sreekumar et al. [4] published a
widely noticed study on the discovery of the role of sarco-
sine in prostate cancer progression. However, the findings
of an immediate re-evaluation of the results in well-defined
samples by Jentzmik et al. [47, 48] suggested that the find-
ings were more likely to be a result of cohort differences
rather than true elevations of sarcosine levels in the urine
of prostatic cancer patients.
At the time we started proteomics research little was known
about the innumerable influencing factors that can hamper
and bias comparisons between different patient groups by
means of increasingly sensitive mass spectrometric meth-
odology. Nearly anything we could imagine led to a de-
tectable and frequently “significant” difference, especially
when the analytes were not absolutely stable and heuristic
bioinformatics were applied. We soon realised that preana-
lytical standardisation is essential, and focused primarily
on establishing protocols for different sample materials
[49–51] and platforms [52]. However, studies of preanalyt-
ical bias can by design only address confounders that are
already known. Other sources of bias might appear during
proteomic or metabolomic studies, or may become appar-
ent after the study is conducted, for example during explor-
atory data analysis. Then it becomes very difficult to cor-
rect for that bias ex posteriori. To enable the detection of
even unknown bias, it might be reasonable to record all
preanalytical variables that could have potential impact on
the samples and their comparison, and to perform explor-
atory analysis in advance of any biomarker modelling ef-
forts.
Fields of potential bias (fig. 2) are the patient preparation
(e.g. premedication or hospitalisation), nutrition (e.g. fast-
ing or standard diet), the exact mode of sampling itself
(e.g. the punctured vein, upright or sitting position), the
sampling time (to standardise circadian effects), the
sampling material (e.g. the batch and brand of syringes
and tubes), the transport conditions of the samples (e.g.
time, temperature, acceleration), the complete sample pre-
processing (centrifugation, pipetting, etc.), the freezing and
thawing speed, the storage temperature and time, and the
occurrence of repeated freezing and thawing cycles.
Special attention should be paid to the selection of the
sampled biomaterial. For MALDI-TOF peptide profiling
of human blood, serum might be a reasonable choice [11,
51], whereas for the investigation of diseases limited to the
brain, cerebrospinal fluid can be necessary [50], because
the concentrations of the analytes are too low in the peri-
pheral blood. Urine is an optimal material for small molec-
ules excreted by the kidneys. However, dilution, contam-
ination and decay can be high, and can impede analysis
and interpretation [53]. For pancreatic disease, pancreatic
juice has been proposed as a promising sample type for pi-
lot studies [54], but the invasiveness of its retrieval pro-
hibits its use for screening. In an even more adverse case,
the fluid enriched with a potential biomarker might be se-
cluded from the circulation (e.g. in a cyst or abscess), ren-
dering blood-based detection impossible despite high local
concentrations.
Additional factors are the time the individual sample waits
for analysis when samples are analysed in batches (e.g. in
the sample tray of a mass spectrometer, or even the poten-
tially temperature-dependent position on a noncooled tray),
the randomness of the analysis order (to avoid continuous
“shift” affecting patient and control samples to a different
extent), and also the ambient conditions (e.g. air humidity
for the cocrystallisation in MALDI-TOF sample prepara-
tion).
A possibility to consider for assessing potential influences
is the use of internal or external markers, which are added
early in the preanalytical pipeline and could be used to
quantify sample degradation or alterations during the
preanalytical handling. However, such markers themselves
introduce bias, and the benefit and the detrimental effects
of their use have to be considered very carefully [55].
Measurement
For proteomics/peptidomics, as well as for metabolomics,
a large number of analytical platforms are available and
the generalisability of their different results is very limited,
even within the results from a single platform [56]. In prin-
ciple, there are two main approaches, the “nontargeted” and
the “targeted”. The “nontargeted” approach is usually ap-
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plied when no prior knowledge about the markers to be
found exists and the method is used to detect the widest
possible range of differential analytes. The “targeted” ap-
proach is selected when a small number of suspected ana-
lytes have to be quantified in order to determine exactly
the differences between groups. Both approaches have ad-
vantages and problems. The “nontargeted” approach allows
the detection of hitherto unknown markers, but is (in gen-
eral) limited in sensitivity and quantitation capabilities, and
generates huge amounts of data, which have to be stored,
processed, and interpreted. In contrast, the “targeted” ap-
proach delivers superior sensitivity and “simple” quantitat-
ive data, which are more easily compared between differ-
ent platforms, but are limited to the analytes the method is
tuned for. For both approaches many vendors produce ma-
chinery and applications, and the technical development is
extremely rapid, leading to a situation in which potential
markers are rarely “externally” confirmed, just because the
groups having suitable cohorts might not have the same
technical platform.
Just as reporting is extremely important in preanalytics, it
is likewise essential for the analytical phase. Besides the
exact instrument settings (which are frequently displayed
in hardly accessible submenus of the device software), data
on inter- and intra-day variation and drift, on the reagents
and the processing steps already performed in the instru-
ment (e.g. peak alignment, etc.) should be mentioned. Of
course, standards have therefore been developed [57, 58],
but their observance is not yet strictly enforced by journal
editors. A fact that is often ignored is bias caused by the
analytical method itself. Mass-spectrometry, for example,
is dependent on ionisation, and this process interferes with
the analytes and can even destroy the most fragile ones.
Other instrument settings, such as column temperature, can
also be problematic for a variety of heat-labile molecules
[59]. Although metabolomics is defined as the analysis of
all metabolites in a certain biological system, there is no
analytical platform covering the whole metabolome [37],
rendering metabolomics sensu stricto impossible at the mo-
ment. Keeping in mind that any metabolomic experiment
must be considered at least as partial, a combination of
different techniques and analytical platforms might resolve
this dilemma, but also introduce distortions in the global
picture of the metabolites owing to different platform-de-
pendent susceptibilities to bias. For general standardisation
and comparability, the application of reference materials
could be helpful, but also extremely difficult because of the
sometimes low stability and wide range of metabolites to
be covered. Probably the most reasonable approach would
be the use of application-specific reference materials in,
for example, “lipidomics” or “glycomics” of human plasma
[60], which would necessitate international collaborative
efforts. Whenever possible, however, “metabolomic” find-
ings should be validated by a transplatform approach, for
example by measuring the analyte identified by mass-spec-
trometry as differentiating between groups also by means
of common and easy available routine methods. If this were
standard, many false-positive “metabolite markers” could
be sorted out before publication and before other groups
waste their time on externally validating them.
Another important fact to realise is that no single meas-
urement is exact, and each result has to be considered in
a probability range influenced by random and systematic
errors. What is common language in laboratory medicine
[61] has to be respelled in “-omics” science. Mass spec-
trometric instruments especially are extremely sensitive to
altered ambient conditions, which severely hampers the re-
producibility of the results. The measurement of standard-
ised reference samples, the introduction of replicates and
the analysis of all study samples in one batch are just a few
recommendations to target this problem. In fact, it is ne-
cessary to remember that in certain situations measurement
errors can sum up and distort any subsequent analysis at-
tempt. On the other hand, this rediscovery of fundament-
al concepts of accuracy and precision in the emerging “-
omics” technologies also offers a chance for conventional
laboratory medicine to redefine handling, accessibility and
presentation of result uncertainty.
Finally, another yet unsolved problem is how we treat
measurements below the limit of detection (LOD). The
fact that the area under a mass-spectrometric curve cannot
be integrated does not mean that the concentration equals
zero. Setting these value to “null” is artificially “left-cen-
soring” the distribution and might lead to negatively biased
ROC estimates [62].
Data processing
The data processing phase of clinical peptidomics or meta-
bolomics studies is another, and probably the most challen-
ging, step in the analytical pipeline. The experience needed
therein covers not only analytical and technical knowledge,
but also profound skills in mathematics, statistics, epidemi-
ology and even programming. The process of familiarisa-
tion with these demanding sciences is usually cumbersome,
but absolutely necessary to understand and correctly in-
terpret the data transformations and results. Unfortunately,
the emerging “-omics” technologies are developing faster
than the relevant curricula. Therefore, researchers have to
manage awkward data formats, beta-phase tools, programs
that were made for other questions and applications, and
visualisations that frequently cover more than two dimen-
sions: It needed, for example, several years and enormous
efforts until the first R-based MALDI tool was released and
able to process *.fid files [63] or ROC curves with confid-
ence bands could be easily and automatically drawn [64].
To compute correlations of metabolic analyses with sever-
al measurements of each study participant, we had to adapt
a tool originally developed for genetic analyses [65, 66],
and the visualisation of the volume under the ROC sur-
face (VUS) had to be drawn using self-made scripts [67],
since this feature is still not available in today’s statistic-
al software. Hence it is always reasonable to be cautious
when vendors praise their software as a “one-click-to-res-
ult” or “one-button” solution. Due to the enormous vari-
ability in analytes, methods, platforms, study designs and
questions, there is no “standard” metabolomics study that
could be completely approached by using a “standard” pro-
gram, even if the proprietary software solutions pretend to
have such capabilities. However, the number of attempts to
standardise more and more aspects of the data processing
phase is increasing every year, and indeed there are stand-
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ardised parts, for example the data formats and reporting
[57], the data sharing [68] or the validation [69].
A major obstacle for the implementation of general data
treatment guidelines is the huge amount of data generated
in, for example, metabolomics experiments, which would
have to be standardised in all its aspects, comprising sever-
al gigabytes of data for the measurement of a single replic-
ate of, for example, human plasma using ultraperformance
liquid chromatography (UPLC) quadrupole time-of-flight
mass spectrometry (Q-TOF) analytics. Despite their on-
going evolution, standard office computers are at an im-
mediate limit when spectra information from hundreds or
thousands of study participants has to be processed com-
paratively at the same time. Because of the reduction in
sensitivity [19], it might not be an optimal recommendation
or “solution” to raise the signal-to-noise ratio (s/n), in order
to reduce the size of the dataset, rendering it appropriate for
a priori insufficient 32-bit hard- and soft-ware. The omis-
sion of a signal-to-noise ratio cut-off might boost the sens-
itivity, but it also demands considerable computing power
even for small peptidomics datasets [19].
This hardware gap could be bridged by applying the emer-
ging so-called “cloud” technologies [70] or, for example,
(GPU-based) parallel computing [71]. Universities (e.g. the
UBELIX cluster of the University of Bern), national
academies (e.g. the Leibniz Supercomputing Centre in Mu-
nich), and institutes (e.g. the Vital-IT of the Swiss Institute
of Bioinformatics) can also provide the necessary resources
and enable rapid processing as well as thorough evaluation
of even large datasets. The development of web-based ser-
vices is another step in the direction of centralised com-
puting [72], but confidentiality, intellectual property and
reproducibility (e.g. by guaranteed availability of the ser-
vice, proper maintenance, and versioning) are important
points that should be clarified in advance. Meanwhile, the
first “R”-packages for integrating different “-omics” ap-
proaches have been released [73], and given the ultrarapid
development, the ever-increasing number of available
packages, and the multi- and grid-processing capabilities of
this open-source platform, major advances in the analys-
is of metabolomics and peptidomics data can be expected
within the next few years.
Besides the technical preconditions and documentation, the
workflow management also is becoming more and more
important. Although the individual settings and parameters
may vary from study to study, the workflow or “pipeline”
itself might be a reasonable target for standardisation
[74–76]. As John Quackenbush stated a decade ago, “re-
porting data transformations is becoming as important as
disclosing laboratory methods. Without an accurate de-
scription of either of these, it would be difficult, if not im-
possible, for the results derived from any study to be rep-
licated” [77].
Interpretation
The last, most neglected and also most intellectual phase
in clinical metabolomics and peptidomics is the interpret-
ation of the results. The conceptual approach, procedure
and subsequent interpretation strongly depend on the aim
of the study – typically to search for “biomarkers” to dis-
tinguish between different study cohorts – and can include
the detection of differences between groups, the evaluation
of their significance, the selectivity of analytes or combin-
ations thereof, the added value in comparison or combina-
tion with conventional disease markers, or even the evalu-
ation of the noninferiority or superiority of a new marker
or model. The farther we step from the trivial “statistic-
ally significant differences” approach, the more complic-
ated and challenging become evaluation and interpretation.
The principal problem is the reduction of complexity: the
huge amount of data we generate with each peptidomics
or metabolomics experiment has to be reduced to clinically
“usable” statements or information, in the case of biomark-
er studies typically expressing the probability of a patient
being in one of the disease classes. A second aspect is the
reduction of the complexity of the biomarker models. The
simpler these models are, the more easily they can be im-
plemented in, for example, standard laboratory information
systems, and, according to Occam’s law, simpler models
are also more likely to be “true”.
There are different strategies for reducing complexity.
First, the study design can be focused to answer one specif-
ic question. In this setting we expect a very limited set of
results, which are easy to interpret and do not need sophist-
icated statistical evaluation. Frequently, however, the study
design is “hypothesis-free” and the full complexity is main-
tained until data analysis. In this case, interpretation is ex-
tremely difficult, and probably impossible, without elabor-
ate multivariate statistical pipelines (fig. 3). Today, most
of the proprietary, usually patched-up, software shipped
with analytical instruments is focused on exploratory data
analysis, for example principal component analysis (PCA)
and other variance-based techniques. This software is com-
monly used to display different groups, classes, or clusters
in the dataset as, for example, score plots. What might
seem reasonable ‒ and certainly is ‒ for the detection of bi-
as does not, on the other hand, either reduce the amount of
input data or answer the right question. In a standard bio-
marker study setup, the question is not “how many groups
are in my sample?”, because one should a priori and by
design know how many groups there are, but rather “how
can I restrict and condense the data to a clinically applic-
able “meta-marker”, which predicts assignment to already
known classes?”. In this situation, the common approach
of exploratory data analysis might be insufficient alone and
should be at least complemented by an inferential strategy.
This transition from exploration to inference is a crucial
step in the “-omics” evolution. The problem is no longer
the sheer amount of data, which can be processed by
powerful computing tools. Rather, it is the amount of in-
formation that can be derived from these data and which
has to be disentangled and reduced to the essential. Un-
fortunately, there is a “comprehensibleness threshold”. Hu-
man perception of complex coherences may be very lim-
ited, and for the acceptance of peptidomic or metabolomic
data at the patient’s bedside it seems essential to provide in-
formation condensed enough to enable a prima vista under-
standing of a marker model, as well as simple application
for the clinician. For these “final” interpretation steps, new
statistical concepts and computational options are emer-
ging: For the modelling of clinical outcome on the basis of
correlated functional biomarkers, a new Bayesian approach
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was suggested by Long et al. [78]. For the incorporation of
replicate information into correlation estimates, Zhu et al.
[66] proposed the R-based CORREP package, which can
be applied not only to genetic data, but also to metabol-
ite data [65]. New comparative study designs have stimu-
lated the development of tools for the simultaneous statist-
ical evaluation of diagnostic markers in multiclass settings
[79] and the extension of the conventional ROC curve to
the third dimension [80].
In addition to the selectivity of any kind of profile or mark-
er its “added value” as compared with the measurement of
the standard disease markers is becoming increasingly im-
portant as “-omics” diagnostics come closer to the bedside
and clinicians have to balance effort and benefit [15, 81].
Noninferiority and equivalence testing also serve as pivotal
techniques when the introduction of a new marker or panel
is to be considered, and today’s computational capacities
enable even computationally intensive confidence interval-
based approaches [67, 82] to be calculated.
Another important feature implemented in recent evalu-
ation tools is the display of the uncertainty inherent to any
modelling approach. With increasing size of our datasets,
the probability that these contain more than one predict-
ive model increases, a fact that still is neglected by many
standard evaluation procedures [67, 83, 84]. Also avoiding
“false positive” discoveries [85] and, especially in the field
of metabolomics, the implementation of pathway data into
modelling procedures and the extraction of pathway altera-
tions from the metabolic data [86] will play an ever grow-
ing role.
Conclusion
Whether all the massive investments made in peptidomics
and metabolomics will condense down to one single clin-
ically useful marker cannot be foreseen at the moment –
and considering the smouldering “success” of proteomics
it is certainly justifiable to be in doubt – but besides open-
ing a window into the disease specificity of degradation
processes and metabolic pathway alterations, clinical pep-
tidomics and metabolomics drive the development of new
concepts for the handling of huge “-omics” datasets con-
taining vast amounts of implied biological and pathway in-
formation – an academic process quite independent of the
analytical improvements introduced by the diagnostics in-
dustry. As relatively recent technologies they are still suf-
fering from the many imperfections, insufficiencies and in-
tricacies genomics and proteomics went through before.
But it is also a chance – to learn from errors already com-
mitted, as well as to apply creatively existing tools and
techniques and develop new ones for extended needs. The
real challenge is still ahead: to integrate and simultaneously
condense results from all the different “-omics” subdiscip-
lines and even conventional analytics to create new, super-
ior “meta-markers”.
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Figures (large format)
Figure 1
The biomarker bottleneck. During the successive phases of the transition of a biomarker from bench to bedside (roughly segmented into
exploratory “discovery”, multicentred “validation”, clinical assay “development”, and large-scale “deployment” phases), the hurdles for successful
evolution are steeply increasing. Researchers face exploding costs and complex regulatory requirements, and they have to cooperate with
competing groups to gain large and independent validation cohorts. Finally, few – if any – markers can be clinically established.
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Figure 2
Potential sources of preanalytical bias.
RT = room temperature.
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Figure 3
Complexity of the conventional “hypothesis-driven” approach (A) compared with “hypothesis-free” study approaches (B & C). Most of the
published metabolomics studies resemble study type C: differences are determined and principal component analysis (PCA) score plots are
frequently drawn. But since complexity is not really reduced, interpreting the data and answering the study questions is difficult and sometimes
impossible. Study type B includes a complexity reduction step (e.g. variable/model selection, see orange circle) and thereby facilitates
interpretation. Elaborate statistics are necessary to perform this reduction, but they are unavoidable since the complexity of the information
contained in the “-omics” data usually exceeds human comprehension (the “comprehensibleness threshold” signifies this limit).
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